Drug application
RYZODEG 70/30 (INSULIN ASPART, INSULIN DEGLUDEC)
Drugs@FDA BLA 203313 · NOVO
Key facts
| Drug name | RYZODEG 70/30 |
|---|---|
| Active ingredients | INSULIN ASPART, INSULIN DEGLUDEC |
| Application type | BLA |
| Application number | 203313 |
| Company | NOVO |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML) |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Sep 25, 2015 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: